News & Updates

Show Multimedia Only

Dupilumab yields rapid, lasting improvement in erythrodermic atopic dermatitis

04 Feb 2023

Treatment with dupilumab helps improve the signs and symptoms of erythrodermic atopic dermatitis, with the improvements occurring as early as the first week and being sustained over time, according to a study. The drug has an acceptable safety profile.

04 Feb 2023

Oral ritlecitinib safe, effective for treatment of active nonsegmental vitiligo

27 Jan 2023

Treatment with oral ritlecitinib improves outcomes in patients with active nonsegmental vitiligo, without any serious adverse events over 48 weeks, results of a study have shown.

27 Jan 2023

Online on par with in-person care for improving outcomes in psoriasis

26 Jan 2023

An online health model appears to be as effective as in-person care for decreasing functional impairment and depressive symptoms in patients with psoriasis, according to a study.

26 Jan 2023

Rituximab confers cardioprotection on pemphigus patients

23 Jan 2023

Treatment with rituximab in patients with pemphigus appears to yield long-term cardiovascular and metabolic protection as compared with conventional immunosuppressants, a study has shown.

23 Jan 2023

Multiple moles, genetic predisposition up risk of second primary melanomas

22 Jan 2023

Individuals with multiple nevi and high genetic predisposition to melanoma appear to have the highest risks of developing second primary melanomas, according to a study.

22 Jan 2023

Lebrikizumab–topical corticosteroid combo improves outcomes in moderate-to-severe AD

16 Jan 2023 by

Treatment with lebrikizumab, when combined with low- to mid-potency topical corticosteroid (TCS), helps reduce disease severity in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD), with a safety profile consistent with that reported in previous AD studies, according to the phase III ADhere trial.

16 Jan 2023

Obesity reduces adalimumab potency against hidradenitis suppurativa

14 Jan 2023

Adalimumab for the treatment of hidradenitis suppurativa appears to be less effective in patients with obesity, a study has found.

14 Jan 2023

JAK inhibitors pose increased risk of developing shingles

12 Jan 2023

Exposure to the Janus kinase (JAK) inhibitors tofacitinib and upadacitinib, as well as to JAK inhibitors as a class, appears to put individuals at increased risk of developing herpes zoster infection, with the risk increasing at higher doses, as reported in a study.

12 Jan 2023

Tralokinumab improves skin microbial dysbiosis in atopic dermatitis

10 Dec 2022

In patients with atopic dermatitis (AD), treatment with the IL-13 cytokine-targeting tralokinumab appears to directly or indirectly improves skin microbial dysbiosis, reports a new trial.

10 Dec 2022

Rituximab yields cardiometabolic protection in pemphigus patients

09 Dec 2022

Treatment with rituximab appears to confer protective effects against long-term cardiovascular and metabolic outcomes in patients with pemphigus as compared with conventional immunosuppressants, according to a study.